{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:55:44Z","timestamp":1794934544953,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"8130","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,9,3]]},"DOI":"10.1038\/s41586-026-10789-w","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:01:43Z","timestamp":1784127703000},"page":"252-261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Modular in vivo antibody\u2013ADC click to reverse drug resistance in tumours"],"prefix":"10.1038","volume":"657","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5980-9379","authenticated-orcid":false,"given":"Cristina","family":"Sim\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1275-1202","authenticated-orcid":false,"given":"Alexander C.","family":"Vanover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3651-0136","authenticated-orcid":false,"given":"Ricardo","family":"D\u2019Oliveira Albanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep Surendra","family":"Panikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayla","family":"Shmuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4421-0179","authenticated-orcid":false,"given":"Alex","family":"Benton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jader","family":"Giraldo-Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5513-022X","authenticated-orcid":false,"given":"Jos\u00e9 M.","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na-Keysha","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai","family":"Keltee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9434-7907","authenticated-orcid":false,"given":"Jingxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrokh","family":"Dehdashti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4772-9339","authenticated-orcid":false,"given":"Patr\u00edcia M. R.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"10789_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu, Z., Li, S., Han, S., Shi, C. & Zhang, Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct. Target. Ther. 7, 93 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"10789_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00743-w","volume":"11","author":"AA Davis","year":"2025","unstructured":"Davis, A. A., Hesse, J., Pereira, P. M. R. & Ma, C. X. Novel treatment approaches utilizing antibody\u2013drug conjugates in breast cancer. NPJ Breast Cancer 11, 42 (2025).","journal-title":"NPJ Breast Cancer"},{"key":"10789_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07608-w","volume":"9","author":"PMR Pereira","year":"2018","unstructured":"Pereira, P. M. R. et al. Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nat. Commun. 9, 5137 (2018).","journal-title":"Nat. Commun."},{"key":"10789_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30142-9","volume":"13","author":"PMR Pereira","year":"2022","unstructured":"Pereira, P. M. R. et al. Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer. Nat. Commun. 13, 2526 (2022).","journal-title":"Nat. Commun."},{"key":"10789_CR5","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2967\/jnumed.122.265172","volume":"64","author":"EL Brown","year":"2023","unstructured":"Brown, E. L. et al. Immuno-PET detects antibody\u2013drug potency on coadministration with statins. J. Nucl. Med. 64, 1638\u20131646 (2023).","journal-title":"J. Nucl. Med."},{"key":"10789_CR6","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.4161\/cbt.6.12.4979","volume":"6","author":"W Zhu","year":"2007","unstructured":"Zhu, W., Okollie, B. & Artemov, D. Controlled internalization of Her-2\/neu receptors by cross-linking for targeted delivery. Cancer Biol. Ther. 6, 1960\u20131966 (2007).","journal-title":"Cancer Biol. Ther."},{"key":"10789_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41587-019-0073-7","volume":"37","author":"JC Kang","year":"2019","unstructured":"Kang, J. C. et al. Engineering a HER2-specific antibody\u2013drug conjugate to increase lysosomal delivery and therapeutic efficacy. Nat. Biotechnol. 37, 523\u2013526 (2019).","journal-title":"Nat. Biotechnol."},{"key":"10789_CR8","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1158\/1535-7163.MCT-17-0296","volume":"17","author":"G Li","year":"2018","unstructured":"Li, G. et al. Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells. Mol. Cancer Ther. 17, 1441\u20131453 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"10789_CR9","doi-asserted-by":"publisher","first-page":"10773","DOI":"10.1073\/pnas.1323934111","volume":"111","author":"B Zhao","year":"2014","unstructured":"Zhao, B., Hemann, M. T. & Lauffenburger, D. A. Intratumor heterogeneity alters most effective drugs in designed combinations. Proc. Natl Acad. Sci. USA 111, 10773\u201310778 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10789_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67840-z","volume":"17","author":"K Borremans","year":"2025","unstructured":"Borremans, K. et al. Expression of antibody\u2013drug conjugate targets in post-mortem samples of breast cancer metastases and normal tissue. Nat. Commun. 17, 1080 (2025).","journal-title":"Nat. Commun."},{"key":"10789_CR11","doi-asserted-by":"crossref","unstructured":"Tsao, L.-C. et al. Trastuzumab\/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis. JCI Insight 7, e155636 (2022).","DOI":"10.1172\/jci.insight.155636"},{"key":"10789_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn, A. F., Janmaat, M. L., Reichert, J. M. & Parren, P. W. H. I. Bispecific antibodies: a mechanistic review of the pipeline. Nat. Rev. Drug Discov. 18, 585\u2013608 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10789_CR13","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","volume":"11","author":"OM Filho","year":"2021","unstructured":"Filho, O. M. et al. Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discov. 11, 2474\u20132487 (2021).","journal-title":"Cancer Discov."},{"key":"10789_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","volume":"35","author":"EA Perez","year":"2017","unstructured":"Perez, E. A. et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J. Clin. Oncol. 35, 141\u2013148 (2017).","journal-title":"J. Clin. Oncol."},{"key":"10789_CR15","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1200\/JCO.2021.39.15_suppl.1023","volume":"39","author":"P Schmid","year":"2021","unstructured":"Schmid, P. et al. BEGONIA: phase 1b\/2 study of durvalumab (D) combinations in locally advanced\/metastatic triple-negative breast cancer (TNBC)\u2014initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). J. Clin. Oncol. 39, 1023\u20131023 (2021).","journal-title":"J. Clin. Oncol."},{"key":"10789_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101792","volume":"5","author":"A Gupta","year":"2024","unstructured":"Gupta, A. et al. EGFR-directed antibodies promote HER2 ADC internalization and efficacy. Cell Rep. Med. 5, 101792 (2024).","journal-title":"Cell Rep. Med."},{"key":"10789_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck, A., Goetsch, L., Dumontet, C. & Corva\u00efa, N. Strategies and challenges for the next generation of antibody\u2013drug conjugates. Nat. Rev. Drug Discov. 16, 315\u2013337 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10789_CR18","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMcibr2213596","volume":"387","author":"BM Zeglis","year":"2022","unstructured":"Zeglis, B. M. & Lewis, J. S. Click here for better chemistry. N. Engl. J. Med. 387, 2291\u20132293 (2022).","journal-title":"N. Engl. J. Med."},{"key":"10789_CR19","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41587-023-01860-2","volume":"41","author":"M Peplow","year":"2023","unstructured":"Peplow, M. \u2018Clicked\u2019 drugs: researchers prove the remarkable chemistry in humans. Nat. Biotechnol. 41, 883\u2013885 (2023).","journal-title":"Nat. Biotechnol."},{"key":"10789_CR20","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5","volume":"40","author":"HC Kolb","year":"2001","unstructured":"Kolb, H. C., Finn, M. G. & Sharpless, K. B. Click chemistry: diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. 40, 2004\u20132021 (2001).","journal-title":"Angew. Chem. Int. Ed."},{"key":"10789_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03880-y","volume":"9","author":"R Rossin","year":"2018","unstructured":"Rossin, R. et al. Chemically triggered drug release from an antibody\u2013drug conjugate leads to potent antitumour activity in mice. Nat. Commun. 9, 1484 (2018).","journal-title":"Nat. Commun."},{"key":"10789_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1021\/acs.bioconjchem.9b00761","volume":"31","author":"A Rondon","year":"2020","unstructured":"Rondon, A. & Degoul, F. Antibody pretargeting based on bioorthogonal click chemistry for cancer imaging and targeted radionuclide therapy. Bioconjug. Chem. 31, 159\u2013173 (2020).","journal-title":"Bioconjug. Chem."},{"key":"10789_CR23","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1038\/s41596-021-00540-2","volume":"16","author":"SM Sarrett","year":"2021","unstructured":"Sarrett, S. M. et al. Inverse electron demand Diels\u2013Alder click chemistry for pretargeted PET imaging and radioimmunotherapy. Nat. Protoc. 16, 3348\u20133381 (2021).","journal-title":"Nat. Protoc."},{"key":"10789_CR24","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1021\/bc8004446","volume":"19","author":"NK Devaraj","year":"2008","unstructured":"Devaraj, N. K., Weissleder, R. & Hilderbrand, S. A. Tetrazine-based cycloadditions: application to pretargeted live cell imaging. Bioconjug. Chem. 19, 2297\u20132299 (2008).","journal-title":"Bioconjug. Chem."},{"key":"10789_CR25","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1073\/pnas.1113466109","volume":"109","author":"NK Devaraj","year":"2012","unstructured":"Devaraj, N. K., Thurber, G. M., Keliher, E. J., Marinelli, B. & Weissleder, R. Reactive polymer enables efficient in vivo bioorthogonal chemistry. Proc. Natl Acad. Sci. USA 109, 4762\u20134767 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10789_CR26","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1002\/anie.200906294","volume":"49","author":"R Rossin","year":"2010","unstructured":"Rossin, R. et al. In vivo chemistry for pretargeted tumor imaging in live mice. Angew. Chem. Int. Ed. Engl. 49, 3375\u20133378 (2010).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10789_CR27","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","volume":"30","author":"K Shitara","year":"2024","unstructured":"Shitara, K. et al. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. Nat. Med. 30, 1933\u20131942 (2024).","journal-title":"Nat. Med."},{"key":"10789_CR28","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/2159-8290.CD-17-1260","volume":"8","author":"SB Maron","year":"2018","unstructured":"Maron, S. B. et al. Targeted therapies for targeted populations: anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma. Cancer Discov. 8, 696\u2013713 (2018).","journal-title":"Cancer Discov."},{"key":"10789_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10120-014-0360-4","volume":"18","author":"AK Nagatsuma","year":"2015","unstructured":"Nagatsuma, A. K. et al. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer 18, 227\u2013238 (2015).","journal-title":"Gastric Cancer"},{"key":"10789_CR30","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/cncr.22445","volume":"109","author":"KL Wang","year":"2007","unstructured":"Wang, K. L. et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 109, 658\u2013667 (2007).","journal-title":"Cancer"},{"key":"10789_CR31","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1158\/1078-0432.CCR-20-0121","volume":"27","author":"S Corso","year":"2021","unstructured":"Corso, S. et al. Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas. Clin. Cancer Res. 27, 3126\u20133140 (2021).","journal-title":"Clin. Cancer Res."},{"key":"10789_CR32","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","volume":"14","author":"Y Gu","year":"2024","unstructured":"Gu, Y., Wang, Z. & Wang, Y. Bispecific antibody drug conjugates: making 1\u2009+\u20091\u2009>\u20092. Acta Pharm. Sin. B 14, 1965\u20131986 (2024).","journal-title":"Acta Pharm. Sin. B"},{"key":"10789_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23793-7","volume":"12","author":"CM Yamazaki","year":"2021","unstructured":"Yamazaki, C. M. et al. Antibody\u2013drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat. Commun. 12, 3528 (2021).","journal-title":"Nat. Commun."},{"key":"10789_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2307\/1932409","volume":"26","author":"LR Dice","year":"1945","unstructured":"Dice, L. R. Measures of the amount of ecologic association between species. Ecology 26, 297\u2013302 (1945).","journal-title":"Ecology"},{"key":"10789_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41421-023-00523-5","volume":"9","author":"X Bai","year":"2023","unstructured":"Bai, X. et al. Structure and dynamics of the EGFR\/HER2 heterodimer. Cell Discov. 9, 18 (2023).","journal-title":"Cell Discov."},{"key":"10789_CR36","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/bjc.2014.442","volume":"111","author":"H Cheng","year":"2014","unstructured":"Cheng, H. et al. EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. Br. J. Cancer 111, 1065\u20131071 (2014).","journal-title":"Br. J. Cancer"},{"key":"10789_CR37","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/543743a","volume":"543","author":"R Mestel","year":"2017","unstructured":"Mestel, R. Cancer: imaging with antibodies. Nature 543, 743\u2013746 (2017).","journal-title":"Nature"},{"key":"10789_CR38","doi-asserted-by":"publisher","first-page":"6311","DOI":"10.1021\/acs.molpharmaceut.4c00777","volume":"21","author":"C Simo","year":"2024","unstructured":"Simo, C., Shmuel, S., Vanover, A. & Pereira, P. M. R. [64Cu]Cu-NOTA-Trastuzumab and [89Zr]Zr-DFO-trastuzumab in xenografts with varied HER2 expression. Mol. Pharm. 21, 6311\u20136322 (2024).","journal-title":"Mol. Pharm."},{"key":"10789_CR39","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz, G. et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. 380, 617\u2013628 (2019).","journal-title":"N. Engl. J. Med."},{"key":"10789_CR40","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783\u20131791 (2012).","journal-title":"N. Engl. J. Med."},{"key":"10789_CR41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4048","volume":"39","author":"K Yamaguchi","year":"2021","unstructured":"Yamaguchi, K. et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01). J. Clin. Oncol. 39, 4048 (2021).","journal-title":"J. Clin. Oncol."},{"key":"10789_CR42","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","volume":"18","author":"T Doi","year":"2017","unstructured":"Doi, T. et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 18, 1512\u20131522 (2017).","journal-title":"Lancet Oncol."},{"key":"10789_CR43","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara, K. et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N. Engl. J. Med. 382, 2419\u20132430 (2020).","journal-title":"N. Engl. J. Med."},{"key":"10789_CR44","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"E van Cutsem","year":"2023","unstructured":"van Cutsem, E. et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 24, 744\u2013756 (2023).","journal-title":"Lancet Oncol."},{"key":"10789_CR45","doi-asserted-by":"crossref","unstructured":"Bardia, A. et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N. Engl. J. Med. 391, 2110\u20132122 (2024).","DOI":"10.1056\/NEJMoa2407086"},{"key":"10789_CR46","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele, F. et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat. Med. 29, 2110\u20132120 (2023).","journal-title":"Nat. Med."},{"key":"10789_CR47","doi-asserted-by":"publisher","first-page":"S507","DOI":"10.1016\/j.annonc.2021.08.611","volume":"32","author":"SM Tolaney","year":"2021","unstructured":"Tolaney, S. M. et al. 328TiP Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09. Ann. Oncol. 32, S507\u2013S508 (2021).","journal-title":"Ann. Oncol."},{"key":"10789_CR48","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","volume":"17","author":"TN Iwata","year":"2018","unstructured":"Iwata, T. N. et al. A HER2-targeting antibody\u2013drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol. Cancer Ther. 17, 1494\u20131503 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"10789_CR49","doi-asserted-by":"crossref","unstructured":"Tolaney, S. M. et al. Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer. N. Engl. J. Med. 394, 551\u2013562 (2025).","DOI":"10.1056\/NEJMoa2508668"},{"key":"10789_CR50","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.123.266392","volume":"65","author":"R Yeh","year":"2024","unstructured":"Yeh, R. et al. First-in-human evaluation of site-specifically labeled 89Zr-pertuzumab in patients with HER2-positive breast cancer. J. Nucl. Med. 65, 386\u2013393 (2024).","journal-title":"J. Nucl. Med."},{"key":"10789_CR51","first-page":"1722","volume":"40","author":"G Walsh","year":"2022","unstructured":"Walsh, G. & Walsh, E. Biopharmaceutical benchmarks 2022. Nat. Nanotechnol. 40, 1722\u20131760 (2022).","journal-title":"Nat. Nanotechnol."},{"key":"10789_CR52","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1039\/b901970g","volume":"39","author":"JC Jewett","year":"2010","unstructured":"Jewett, J. C. & Bertozzi, C. R. Cu-free click cycloaddition reactions in chemical biology. Chem. Soc. Rev. 39, 1272\u20131279 (2010).","journal-title":"Chem. Soc. Rev."},{"key":"10789_CR53","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s44160-021-00017-w","volume":"1","author":"MG Finn","year":"2022","unstructured":"Finn, M. G., Kolb, H. C. & Sharpless, K. B. Click chemistry connections for functional discovery. Nat. Synth. 1, 8\u201310 (2022).","journal-title":"Nat. Synth."},{"key":"10789_CR54","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/s41596-023-00825-8","volume":"18","author":"D Bauer","year":"2023","unstructured":"Bauer, D., Sarrett, S. M., Lewis, J. S. & Zeglis, B. M. Click chemistry: a transformative technology in nuclear medicine. Nat. Protoc. 18, 1659\u20131668 (2023).","journal-title":"Nat. Protoc."},{"key":"10789_CR55","doi-asserted-by":"publisher","first-page":"13518","DOI":"10.1021\/ja8053805","volume":"130","author":"ML Blackman","year":"2008","unstructured":"Blackman, M. L., Royzen, M. & Fox, J. M. Tetrazine ligation: fast bioconjugation based on inverse-electron-demand Diels\u2013Alder reactivity. J. Am. Chem. Soc. 130, 13518\u201313519 (2008).","journal-title":"J. Am. Chem. Soc."},{"key":"10789_CR56","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1021\/acs.molpharmaceut.2c00220","volume":"19","author":"CA Maitz","year":"2022","unstructured":"Maitz, C. A. et al. Pretargeted PET of osteodestructive lesions in dogs. Mol. Pharm. 19, 3153\u20133162 (2022).","journal-title":"Mol. Pharm."},{"key":"10789_CR57","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","volume":"29","author":"JY Li","year":"2016","unstructured":"Li, J. Y. et al. A biparatopic HER2-targeting antibody\u2013drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell 29, 117\u2013129 (2016).","journal-title":"Cancer Cell"},{"key":"10789_CR58","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-2468","volume":"85","author":"J Giraldo-Guzman","year":"2025","unstructured":"Giraldo-Guzman, J. et al. Abstract 2468: automated co-registration of histology and mass spectrometry imaging for enhanced prostate cancer pathomics. Cancer Res. 85, 2468 (2025).","journal-title":"Cancer Res."},{"key":"10789_CR59","doi-asserted-by":"crossref","unstructured":"Simo, C., Vanover, A. C., Azevedo, E. C. & Pereira, P. M. R. MIB guides: [89Zr]Zr-DFO-trastuzumab and [64Cu]Cu-NOTA-trastuzumab for preclinical cancer imaging. Mol. Imaging Biol. 27, 506\u2013517 (2025).","DOI":"10.1007\/s11307-025-02022-3"},{"key":"10789_CR60","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3892\/or.2013.2547","volume":"30","author":"Y Yamashita-Kashima","year":"2013","unstructured":"Yamashita-Kashima, Y., Shu, S., Harada, N. & Fujimoto-Ouchi, K. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model. Oncol. Rep. 30, 1087\u20131093 (2013).","journal-title":"Oncol. Rep."},{"key":"10789_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58266-8","volume":"16","author":"LC Tsao","year":"2025","unstructured":"Tsao, L. C. et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat. Commun. 16, 3167 (2025).","journal-title":"Nat. Commun."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10789-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10789-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10789-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:05:08Z","timestamp":1788343508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10789-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":61,"journal-issue":{"issue":"8130","published-print":{"date-parts":[[2026,9,3]]}},"alternative-id":["10789"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-10789-w","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"19 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.M.R.P. serves as a consultant for Merck. All the remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}